Literature DB >> 2228838

Serum protein binding and extravascular diffusion of methoxyimino cephalosporins. Time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate.

F Scaglione1, M Raichi, F Fraschini.   

Abstract

A new approach to the study of the distribution pharmacokinetics of variably bound beta-lactams is to plot the concentration time course of their free (dialysable) and total (free and bound) forms. In the present study, the 6-h concentration time course was plotted of the total and free concentrations of cefotaxime and ceftriaxone in serum and pleural exudate in 12 patients per group, after iv dosing with 1 g of either cefotaxime or ceftriaxone. Samples were taken at 0.5, 1, 1.5, 2, 3, 4 and 6h after dosing. The results of a study of similar design, but conducted over 24 h in ten patients per group, following iv dosing with either cefotaxime 1 g 12-hourly or ceftriaxone 1 g daily are also reported. Samples were taken at 0.5, 1, 1.5, 2, 4, 6, 8, 12, 14, 16 and 24 h after dosing. Areas under the curve of free cefotaxime in pleural fluid were greater than those of free ceftriaxone, in both the 6 h (+54.6%) and 24 h studies (+29.8% after 12 h and +71.0% after 24 h). The free cefotaxime/free ceftriaxone Cmax ratio was 1.75 in the 6 h study. Cefotaxime was superior to ceftriaxone in terms of the diffusion of the free (antibacterially active) fraction into a typical inflammatory exudate. Assessment of the effects of protein binding must be taken into account in antibiotic pharmacokinetic profiles.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2228838     DOI: 10.1093/jac/26.suppl_a.1

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  13 in total

1.  BTS guidelines for the management of pleural infection.

Authors:  C W H Davies; F V Gleeson; R J O Davies
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

2.  Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin.

Authors:  S K Nath; G A Foster; L A Mandell; C Rotstein
Journal:  Can J Infect Dis       Date:  1995-01

Review 3.  Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability.

Authors:  Federico Pea; Pierluigi Viale; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 5.  Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem.

Authors:  K P Klugman; C Feldman
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

6.  Influence of assay methodology on the measurement of free serum ceftriaxone concentrations.

Authors:  S J Kohlhepp; D N Gilbert; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Pleural infection-current diagnosis and management.

Authors:  Andrew Rosenstengel
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

8.  Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.

Authors:  Yu-Chia Hsieh; Kuang-Yi Chang; Yi-Chuan Huang; Hsiao-Chuan Lin; Yu-Huai Ho; Li-Min Huang; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

9.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

Review 10.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.